Pre-Prescribing Assessment for Cholestyramine
Before prescribing cholestyramine, you must conduct a comprehensive medication review to identify and manage potential drug interactions, as this is the single most critical safety consideration. 1
Mandatory Medication Review
Review all concurrent medications and adjust timing to prevent binding interactions. Cholestyramine binds numerous drugs, reducing their absorption and potentially causing therapeutic failure or toxicity 1, 2.
High-Risk Medications Requiring Separation:
- Thyroid preparations (levothyroxine)
- Warfarin (risk of bleeding if absorption reduced)
- Digoxin (narrow therapeutic index)
- Thiazide and loop diuretics (hydrochlorothiazide, furosemide)
- Antibiotics (tetracycline, penicillin G)
- Anticonvulsants (phenobarbital, phenytoin)
- Estrogen-containing drugs (oral contraceptives)
- Mycophenolic acid
- Propranolol
- Phenylbutazone
Dosing Rule: Administer all other medications at least 1 hour before or 4-6 hours after cholestyramine 1, 2. A 3-hour window may be adequate based on gastric emptying studies, but the conservative 4-6 hour window is recommended when drug interactions cannot be excluded 1.
Assess for High-Risk Clinical Conditions
Contraindications and Cautions:
Constipation Assessment 2:
- Evaluate for pre-existing constipation
- If present, start with 1 pouch/scoop once daily for 5-7 days
- Counsel on increased fluid and fiber intake
- Consider prophylactic stool softener
- Critical: Avoid constipation in patients with symptomatic coronary artery disease, as it may aggravate hemorrhoids and increase cardiac risk
Renal Function and Volume Status 2, 3:
- Check for renal insufficiency or volume depletion
- Cholestyramine (a chloride-form anion exchange resin) can cause hyperchloremic metabolic acidosis, especially in:
- Patients with renal insufficiency
- Volume-depleted patients
- Those receiving concomitant spironolactone
- Younger/smaller patients receiving relatively higher doses
Recent Abdominal Surgery 4:
- Exercise caution if starting within 3 months of abdominal surgery (rare risk of intestinal obstruction from adhesions)
Baseline Laboratory Considerations
No Routine Vitamin Testing Required at Baseline
The 2020 Canadian Association of Gastroenterology guideline explicitly states no recommendation for or against measuring fat-soluble vitamin levels at baseline 1. The evidence is very low certainty, and vitamin deficiencies are rare.
However, be aware of potential long-term risks:
- Vitamin K deficiency: Can cause hypoprothrombinemia/bleeding (rare, occurs weeks to years after initiation) 1, 2
- Folate deficiency: Reported with long-term use 2, 4
- Fat-soluble vitamins (A, D, E, K): Theoretical risk due to impaired fat absorption 1, 2
Practical Approach:
- No routine baseline vitamin testing needed
- Consider baseline INR if patient has bleeding risk factors or takes anticoagulants
- Supplement vitamins A, D, and K only if deficiency occurs 1
- Consider folate supplementation in high-risk patients (pregnancy, chronic use) 2, 4
Patient-Specific Considerations
Pregnancy/Breastfeeding: Document pregnancy status 2
Pediatric Patients:
- Higher risk of hyperchloremic acidosis due to relatively higher doses 2
- Folate deficiency may occur even with low doses 4
- Consider vitamin D supplementation 4
Lipid Monitoring (if prescribed for hypercholesterolemia):
- Baseline lipid panel
- Monitor serum triglycerides periodically (cholestyramine can increase triglycerides by 10-17%) 2
Common Pitfalls to Avoid
- Failing to separate medication timing: This is the most common and preventable error
- Starting full dose in constipated patients: Always start low and titrate slowly
- Overlooking spironolactone co-administration: Increases acidosis risk
- Assuming therapeutic trial failure excludes bile acid diarrhea: Up to 44% may not respond to cholestyramine but respond to colesevelam 5
- Routine vitamin monitoring: Not evidence-based and not recommended 1